Increased serum amyloid A as potential diagnostic marker for lung cancer: a meta-analysis based on nine studies by unknown
RESEARCH ARTICLE Open Access
Increased serum amyloid A as potential
diagnostic marker for lung cancer: a meta-
analysis based on nine studies
Rong Biaoxue1,2*, Liu Hua3, Gao Wenlong4 and Yang Shuanying5
Abstract
Background: Previous studies have disclosed that serum amyloid A (SAA) is likely involved in the lung cancer
pathogenesis and progression. We performed a systematic evaluation and meta-analysis to disclose the correlation
between the expression of SAA and lung cancer and to evaluate its value for lung cancer diagnosis.
Methods: We searched the relevant articles from the databases of Medline, Embase, Cochrance Library and Web of
Science and calculated the standardized mean difference (SMD) with 95% confidence interval (CI) to assess the
expression difference of SAA between lung cancer and normal patients. Moreover, we counted the positive rate,
sensitivity and specificity and drew a summary receiver operating characteristic curve (SROC) to evaluate the
diagnostic value of SAA for lung cancer.
Results: A total of nine studies with 1392 individuals were included in this analysis. The results showed an increased
SAA was correlated with the incidence of lung cancer (P < 0.001), especially with the lung squamous cell carcinoma
(LSCC) (p = 0.012). The overall sensitivity and specificity of SAA for discerning lung cancer was 0.59 (95% CI: 0.54–0.63)
and 0.92 (95% CI: 0.88–0.95), respectively. The area under the SROC curve was 0.9066 (SE = 0.0437).
Conclusions: Increased SAA in lung cancer was intimately correlated with the development and progression of lung
cancer. A higher specificity of SAA suggested that it should be a significant biomarker for discerning lung cancer from
normal individuals, especially for LSCC (p = 0.012).
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Background
Lung cancer has become the first cause of cancer-
associated death in the world [1]. This is a consistent
opinion that early diagnosis and individualized therapy
are conducive to improve the prognosis of lung cancer
[2]. Many studies have demonstrated that abnormal
protein expressions and gene mutations are correlated
with the ontogenesis and progression of lung cancer [2],
and reliable biomarkers derived from these abnormal
molecules are more likely to help make the medical
decision for individualized therapy [3]. We also know
that the high mortality of lung cancer is mainly due to
early metastasis and progression, and early diagnosis of
lung cancer can increase the 5-year survival rate from 15
to 80 % [4]. Thus, new technology on early diagnosis
and therapies are greatly required.
Recently, chronic inflammation has been showed to be
associated with tumor progression, and many inflammatory
factors could serve as diagnostic and prognostic biomarkers
for special tumors [5]. There is common view that inflam-
mation can become chronic processes that may promote
angiogenesis and proliferation of cells, thus it may play a
clear role in carcinogenesis and pathogenesis [6]. Serum
amyloid A (SAA), a kind of cytokine-induced, acute inflam-
matory response proteins, has been known to be likely
involved in cancers [7]. Research shows that liver is mainly
workplace for producing SAA protein which can stimulates
the production of various cytokines, and SAA plays an
important role in acute immune response [8]. SAA protein
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in blood of patients with cancer often rises at its early stage,
which have been identified both by immunochemistry and
by proteomics methods in different cancers, such as lung,
ovarian, renal, uterine, nasopharyngeal cancer and in
melanoma [7].
Up to now, lung cancer, a very common malignant
tumor, has been considered as an inflammatory disease,
and the development of lung cancer correlates various
cell factors and inflammatory mediators. Previous studies
have specially investigated the relationship between SAA
and lung cancer. These studies suggest that higher SAA
can distinguish lung cancer patients from healthy individ-
uals as well as predict the prognosis of lung cancer [9],
which may be a potentially non-invasive biomarker for lung
cancer. Here, we reviewed the medical literature as com-
pletely as possible, and conducted a meta-analysis to show
the relationship between the expression of SAA and lung
cancer and evaluate its value for lung cancer diagnosis.
Methods
Literature searching
The databases that we searched studies on SAA and lung
cancer included Medline, Embase, Cochrance Library and
Web of Science. The time scope that we defined was from
the start of each database up to June 2016. The key words
that we used for searching literature included: “lung
cancer,” “lung malignancy,” “lung malignant tumor,” “lung
neoplasms,” “serum amyloid A,” and “SAA.” We also
conducted secondary searches for additional studies that
regarding the SAA and lung cancer from the reference
lists of included studies.
Inclusion and exclusion criteria of literature
The inclusion criteria: (1) patients in study must be
histologically diagnosed with lung cancer; (2) must be
case–control or cohort association studies; (3) detection
method of CAA must be able to show the continuous
variables; (4) studies must have reported sufficient quanti-
tative data; and (5) the methods of data collection and
analysis must be statistically acceptable. The exclusion
criteria: (1) non-original reports (such as abstracts, letters,
editorials and expert opinions and case reports); (2) did
not report clearly serum level of SAA with continuous
variables; (3) did not contain distinctively normal control;
(4) patients had been given the chemotherapy and surgery
before taking blood samples; and (5) non-human studies.
Extraction of study variables
The extracted data included: (1) authors, countries and
publication date; (2) study design and case number of
different groups; (3) gender and age of patients; (4) tumor
node metastases (TNM) classification of lung cancer pa-
tients; (5) histological classification; (6) detection method
of SAA; (7) SAA level; (8) the number of true positives,
true negatives, false positives, and false negatives.
Methodological quality assessment
We adopted the guidelines of the QUADAS-2 [10, 11]
(maximum score 14) tool to assess the methodological
quality of included studies, in which appraisal is performed
by empirical evidence, expert opinion, and formal consen-
sus on assessing the quality of primary studies of diagnostic
accuracy [11]. In order to reduce the bias and improve the
reliability, two authors independently assessed and reached
a consensus. If there were a discrepancy, we would invite
another expert to discuss it and reach a consistent opinion.
Statistical analysis
We performed the statistical analysis according to the
following research idea. The standardized mean difference
(SMD) and their 95% confidence intervals (CI) of lung can-
cer associated with the SAA was calculated directly from
the data given in the eligible studies using two different
meta-analysis approaches (fixed effect method and random
effect method). The heterogeneity test between studies was
assessed by the Chi-square test and I2. In the absence of
heterogeneity, we used the fixed effects method, otherwise
the random effect method was used. The overall effect of
meta-analysis was tested using Z-scores with a significance
of being set at p <0.05. We also ran a sensitivity analysis to
determine whether the overall effect was affected by indi-
vidual study. The publication bias was evaluated using
Begg’s and Egger’s test respectively. Moreover, we drew a
summary receiver operating characteristic (SROC) curve to
determine the joint distribution of sensitivity and specificity.
Statistical analysis was performed using SPSS (Version 22.0,
Chicago, USA), RevMan 4.2 (Cochrane Collaboration),
Meta DiSc statistical software (Version 1.4, Madrid, Spain),
and Stata version 12.0 (TX, USA). All the tests were two-
sided and the significant level was 0.05.
Results
Searching of literature
Initially, a searching for the medical literature related to
SAA and lung cancer identified 39 studies, and added
two reports that were from the bibliographies of relevant
articles. Of these 41 articles, 31 seemed to be eligible for
the inclusion criteria. Subsequently, fifteen studies were
excluded because of the following reasons: eight did not
provide useful data; one was duplication of another study;
three were not studies on human; and three had flaws on
statistical design. However, we had to abandon seven of 16
remaining articles because they were short of clear control
groups. Finally, nine publications [4, 9, 12–18] that ful-
filled all of the inclusion criteria were recruited for the
further analysis (Fig. 1).
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Studies description
A total of nine studies with 1392 patients included in this
analysis, and ranged in study size from 34 [13] to 380 [4]
patients, and ranged in age from 32 to 87 years old [14].
The studies were performed in East Asia [4, 9, 15–17],
Europe [18] and America [12–14]. The histological classifi-
cation of lung cancer mainly contained lung adenocarcin-
oma (LAC) (381 patients), lung squamous cell carcinoma
(LSCC) (347 patients) and small cell lung cancer (195 pa-
tients). We established a meta-analysis database according
to the extracted information (Table 1).
Study quality assessment
Tables 2 showed general information of included studies.
Of these studies, five were retrospective [4, 13, 15, 16, 18],
one was retrospective [12], and the other three studies did
not report they were prospective or retrospective [9, 14, 17].
In addition, five studies tested the concentration of SAA
using enzyme-linked immunosorbent assays (ELISA)
[4, 13, 14, 16, 18], and the rest using competitive bind-
ing radioimmunoassay [12], protein chip array [17],
quantitative analysis [15] and latex nephelometry [9]
respectively. We assessed the quality of studies according to
Fig. 1 Flow chart of selection process for studies included in meta-analysis
Table 1 Description of the included studies
Authors Year All cases
(control/
cancer)
Age (years) Gender (Male/female) (N) Histology of lung cancer (N) Tumor
Stage of
lung cancer
Control Lung cancer Control Lung cancer LAC LSCC SCLC Others
Benson MD [12] 1986 100 (50/50) 37 ± 1.9 61.1 ± 1.2 50/0 50/0 5 29 10 NA I-IV
Howard BA [13] 2003 34 (15/19) 50.7 (23–77) 22/12 17 2 0 NA
Khan N [14] 2004 50 (25/25) 62.9 (46–83) 66.1 (47–87) 16/9 16/9 9 6 NA 8 I-IV
Dai S [16] 2007 218 (43/175) NA NA NA NA 59 78 38 0 NA
Liu DH [17] 2007 275 (82/194) NA 65 (41–76) NA 135/58 65 97 31 0 I-IV
Cho WC [15] 2010 189 (35/154) NA 65.5 ± 0.9 NA 129/25 50 53 38 13 I-IV
Sung HJ [4] 2011 380 (140/240) 59 (37–84) 57 (32–79) 96/44 217/53 140 50 50 0 I–IV
Dowling P [18] 2011 109 (30/79) 56.5 ± 7 61 ± 9.3 15/15 31/24 36 17 26 0 IIIB–IV
Kanoh Y [9] 2013 37 (13/24) 62.6 (53–72) 66.2 (52–79) NA NA 24 0 0 I-IV
NA unavailable; N cases; LAC lung adenocarcinoma; LSCC lung squamous cell carcinoma; SCLC small cell lung cancer
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the QUADAS-2 scoring system. Overall, the QUADAS-2
scores of six studies was more than 10 [4, 12, 14, 15, 17, 18]
and that of three less than 10 [9, 13, 16].
Heterogeneity test
The Chi-square value for the heterogeneity test of nine
studies was 144.93 with 8° of freedom (d.f.) and P < 0.05,
which meant the presence of heterogeneity in these
studies. Subsequently, we reviewed each of included
studies carefully from different aspects, and confirmed
that the different detection methods of SAA contributed
to the heterogeneity. However, there was a very good
clinical homogeneity in intention and design of study in
selected studies. It is common opinion about meta- ana-
lysis that clinical homogeneity is more crucial than data
alone, and we could decrease this risk of heterogeneity
through a method of subgroup analysis as much as pos-
sible. Thus, we finally used the random-effect model to
perform this analysis [11].
Comparison of SAA level between lung cancer and
healthy individuals
As shown in Table 3, eight studies compared the expression
level of SAA in lung cancer and healthy group. The weight
of included studies ranged from −2.40% to −9.76%, and the
pooled SMD was −4.88 and 95% confidence interval (CI)
were −6.03 to −3.74) (Fig. 2), which indicated that patients
with lung cancer had a higher SAA level than those of
healthy group. The results indicated that higher SAA
was a concomitant event of lung cancer (z = 8.36, P <
0.001).
Table 2 Methodology and quality of inclined studies
Authors Year Research design Country Asians/
Caucasians
Test method Measurement units QUADAS
Benson MD [12] 1986 Prospective Indiana 0/100 Competitive binding
radioimmunoassay
u/ml 12
Howard BA [13] 2003 Retrospective USA 0/19 ELISA ng/mL 7
Khan N [14] 2004 NA North Carolina 0/50 MALDI-TOF; ELISA ng/mL 10
Dai S [16] 2007 Retrospective China 175/0 SELDI-TOF-MS; ELISA Peak intensities 9
Liu DH [17] 2007 NA China 275/0 Protein Chip Array Peak intensities 10
Cho WC [15] 2010 Retrospective Hong Kong 189/0 SELDI-TOF; quantitative analysis Peak intensities; ug/mL−1 11
Sung HJ [4] 2011 Retrospective South Korea 380/0 LC-ESI-MS/MS Analysis; ELISA ug/mL 12
Dowling P [18] 2011 Retrospective Ireland 0/109 ELISA ug/mL 10
Kanoh Y [9] 2013 NA Japan 37/0 Latex nephelometry ug/mL 7
QUADAS quality assessment for studies of diagnostic accuracy (maximum score 14); ELISA enzyme-linked immunosorbent assays; MALDI-TOF matrix assisted laser
desorption ionization time of flight; SELDI-TOF-MS surface-enhanced laser desorption/inionation-time of flight-mass spectra; LC-ESI-MS/MS liquid chromatography-
electrospray ionisation-tandem mass spectrometry NA unavailable
Table 3 Data extract of SAA expression in control and cancer patients
Author Concentration of SAA (Mean ± standard deviation) Positive /all (N) Diagnostic test
(2 × 2 table)
Control All cancer cases LAC LSCC SCLC Control Lung cancer TP FP FN TN
Benson MD [12] 135 ± 31 1880 ± 251 1460 ± 494 1923 ± 317 1118 ± 317 14/50 45/50 45 14 5 36
Howard BA [13] 34.1 286 NA NA NA 1/15 15/19 15 1 4 14
Khan N [14] 43.8 ± 9.65 83.5 ± 19.5 NA NA NA 4/25 14/25 14 4 11 21
Dai S [16] 2.15 ± 0.73 18.48 ± 21.22 NA NA NA NA NA NA NA NA NA
Liu DH [17] 2.1 ± 0.7 19.3 ± 20.6 15.1 ± 22.4 34.3 ± 20.2 25.7 ± 26 0/82 95/193 95 0 98 82
Cho WC [15] 0.109 ± 0.033 1.872 ± 0.212 NA NA NA NA NA NA NA NA NA
17.06 ± 2.55 710.77 ± 250.42
Sung HJ [4] 13.89 ± 37.18 190.49 ± 234.70 190.49 ± 134.70 302.76 ± 305.21 116.38 ± 81.13 7/140 90/170 90 7 80 133
Dowling P [18] 9.8 NA 141.6 54.8 172.2 NA NA NA NA NA NA
Kanoh Y [9] 8.2 ± 10.55 158 ± 448.7 NA NA NA 0/13 24/24 24 0 0 13
N, cases; NA, unavailable; true positive; LAC lung adenocarcinoma; LSCC lung squamous cell carcinoma; SCLC small cell lung cancer; FP false positive; FN false
negative; TN true negative
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Comparison of SAA level in different histological
classification of lung cancer
As shown in Table 3, three studies [4, 12, 17] compared the
SAA level between LAC and LSCC. The random-effect
combined SMD was −0.80 (95% CI −1.12 to −0.48;
Z = 4.88, P < 0.001), indicating SAA level was higher in
LSCC than in LAC. Comparing LAC with SCLC, the
random-effect combined SMD was 0.28 (95% CI −0.56 to
1.13; Z = 0.65, P = 0.515), indicating no difference was
confirmed. However, the random-effect combined SMD
that resulted from the comparison between LSCC and
SCLC was 1.15 (95% CI 0.25 to 2.04; Z = 2.52, P = 0.012),
demonstrating that SAA level in LSCC was higher than in
SCLC. To conclude, the LSCC displayed the highest SAA
Fig. 2 Comparison of SAA level between lung cancer patients and healthy individuals. Patients with lung cancer showed a higher SAA value than
those of healthy individuals (z = 8.36, P < 0.0001); SAA, serum amyloid A; ELISA, enzyme-linked immunosorbent assays; CI, confidence interval
Fig. 3 Comparison of SAA level in different histological classification of lung cancer. SAA level was higher in LSCC than in LAC and SCLC,
demonstrating that SAA may specially play a significant role in LSCC; LAC, lung adenocarcinoma; LSCC, lung squamous cell carcinoma; SCLC,
small cell lung cancer; CI, confidence interval
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level among the three histological type of lung cancer
(LAC, LSCC and SCLC), implying that SAA may be
biomarker of LSCC especially (Fig. 3).
Analysis of sensitivity and publication bias
The sensitivity analysis showed that the exclusion of studies
on an individual basis did not substantially modify the
estimators and affect the final statistical efficacy, with a
SMD pool oscillating between −2.40 and −9.76 (Fig. 4a).
We employed the Egger test and Begg’s Test to adjudge
whether there was a publication bias or not. The results
showed that Z value of the Egger test was −1.42 (Pr > |Z| =
0.25), and T value of Begg’s Test was −0.99 (P > |t| = 0.386).
With the fact that, no publication bias was considered
(Fig. 4b).
Sensitivity and specificity of SAA for distinguishing lung
cancer
As shown in the forest plot of the sensitivity (Fig. 5a),
the sensitivity of SAA in included studies ranged from
0.53 to one (pooled sensitivity = 0.59; 95% confidence
interval = 0.54 to 0.63). However, the pooled specificity
of SAA for distinguishing lung cancer reached up to
0.92 (95% CI, 0.88 to 0.95) (ranged from 0.72 to one),
which demonstrated that increased SAA had higher
specificity in discerning lung cancer (Fig. 5b).
Fig. 4 Analysis of sensitivity and publication bias. a For comparison of SAA level between lung cancer and healthy individuals, exclusion of
studies on an individual basis did not substantially modify the estimators; b Z value of the Egger test was −1.42 (Pr > |z| = 0.25), implied that there
was no publication bias for these studies
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Diagnostic accuracy of SAA for discerning lung cancer
The overall diagnostic odds ratio (DOR) of included studies
were 27.52 (P = 0.0642), with the scope ranged from 6.68 to
1323 in these studies (Fig. 6a). Figure 6b summarized the
test performance of each study by using the SROC curve,
and the balanced point for sensitivity and specificity (the
Q‑value) was 0.8384. The area under the curve (AUC) was
0.9066, indicating that the overall accuracy was impressive.
Discussion
Now, lung cancer has become the leading cause of
malignancy-related deaths in the world [17, 19], the 5-
year survival rate for lung cancer is only slightly better
than 10%. Lung cancer exhibits the highest mortality of
all cancers mainly because most patients have developed
into the advanced stage when the diagnosis of disease is
confirmed [4]. People believed that stable biomarkers
which can be routinely measured in easily accessible
samples effectively help make early-stage diagnosis for
lung cancer [20]. Blood is an easily accessible and rich
body fluid. Research shows that blood plasma and serum
contain specific proteins that provide potential circulat-
ing biomarkers [21]. For example, the level of acute-
phase SAA often increases in cancer patients, even at its
early stage. This fact was registered in different common
cancers, such as lung, ovarian, renal, uterine, and naso-
pharyngeal cancer and in melanoma [7].
In this study, we reviewed the relevant studies compar-
ing the expression of SAA between lung cancer and
healthy individuals and found that patients with lung
cancer showed a higher SAA level than those of healthy
group. This result indicated that a higher SAA level
certainly correlated with occurrence and development of
lung cancer and that SAA could be an indicator of lung
cancer. We noticed that there was methodology hetero-
geneity that existed between included studies, but we
found that included studies had a very good clinical
homogeneity. For instance, no biases of age and diagno-
sis were observed in these studies. Moreover, patients in-
cluded in these studies were from East Asia, Europe and
America, which embodied the globalization and thus
eliminated the ethnic bias. In order to strength the reli-
ability of results, we made a comparison of SAA positive
rate and showed that SAA positive rate of patients with
lung cancer was higher than that of healthy individuals.
We also found that most of studies had a moderate to
higher quality assessed by using the QUADAS-2 scoring
system. Subsequent analysis of sensitivity further
showed that the exclusion of studies on an individual
basis did not substantially modify the overall effect of
meta-analysis. Bias evaluation [11] in our analysis sug-
gested that there was not a significant publication bias.
Together, the results of this meta- analysis should be more
stable. Previous studies have found that SAA can distin-
guish lung cancer patients from healthy controls as well as
predict prognosis of lung cancer [8, 12, 15, 17]. SAA is se-
creted during the acute phase of inflammation, including
invertebrates and vertebrates, suggests that SAA has an
essential role in all animals including humans [15]. Study
point out that overexpression of SAA is always correlated
with inflammation and acute-phase responses [16]. Fur-
ther, investigation on cancers reveals that chronic inflam-
mation is associated with development and progression of
malignant tumors, and inflammatory factors can be
Fig. 5 Sensitivity and specificity of SAA for the diagnosis of lung cancer. a Pooled sensitivity was 0.59; 95 % CI was 0.54 to 0.63; b pooled
specificity was 0.92, which suggested that SAA has a relatively higher specificity; CI, confidence interval
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applied as diagnostic and prognostic indicators for some
malignant tumors. SAA is a kind of inflammatory factor,
adding our findings, thus showing that there is strong re-
lationship between chronic inflammation and incidence of
lung cancer.
It is likely that SAA in pulmonary inflammation may be
temporarily elevated and recovered soon after the elimin-
ation of infection, but not the same in cancers, which may
represent a primary difference between benign and malig-
nant diseases of lung [17]. In our analysis, we were excited
to find that LSCC displayed a much higher SAA level than
LAC and SCLC, which gave us a very significant clue that
we might specially use SAA for discerning LSCC from
others. The results also confirmed by subsequent evidence
that overexpression of SAA even was detected western blot
analysis in LSCC, but not in others [4]. It is widely known
that there has still no efficient biomarker for LSCC diagnosis
so far. As an indicator of the potential usefulness of SAA in
the diagnosis of lung cancer, in particular in LSCC, we ought
to investigate deeply the role of SAA in LSCC in the future.
It is unassailable, as a diagnostic marker, a good sensitiv-
ity and specificity are very important. In this meta-analysis
of diagnostic test we found that the increase of SAA has a
higher specificity (0.92; 95% CI: 0.88-0.95) for discerning
lung cancer. However, the pooled sensitivity was only 0.56
(95% CI: 0.54-0.63), which suggested that SAA has a better
role for distinguishing lung cancer but not for screening.
Thus, when biopsy of tumor tissue is absent or insufficient
in clinic, we may use the SAA as an indicator to discern
lung cancer. However, the absence of increased SAA should
not mean the impossibility of lung cancer. The DOR always
indicate the test accuracy of a biomarker that bind the com-
promise of sensitivity and specificity to a quantitative data.
People believed that a higher DOR values suggest a higher
accuracy of diagnosis. In our analysis, the pooled DOR was
27.52, supporting that the SAA assay could be advanta-
geous in the diagnosis of lung cancer. The definitive diag-
nosis of lung cancer usually requires tissue biopsies of
adequate size. However, sometimes the tissues for path-
ology biopsy were insufficient, and then a test with SAA
would help improve the differential diagnosis. The SROC
curve has been recommended to represent the perform-
ance of a diagnostic test [11]. Our analysis showed that the
AUC of SAA was 0.9066, which indicated that the SAA has
good value in terms of the discerning diagnosis of lung can-
cer. From the present data, we think that every patient with
Fig. 6 Diagnostic accuracy of SAA to lung cancer. a The overall Diagnostic Odds Ratio (DOR) of included studies were 27.52 (p = 0642), which
indicated that SAA had a ability to discern lung cancer; b The balanced point for sensitivity and specificity (the Q‑value) was 0.8384. The area under
the curve (AUC) was 0.9066, indicating that the overall accuracy was impressive. SORC, summary receiver operating characteristic; OR, odds ratios
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suspected lung cancer should undergo the test of SAA.
Patients with positive SAA level should undergo further
invasive procedures biopsies, and produce a final diagnosis.
The limitations of this study are as follows: first, some
studies had small size; second, some studies had relatively
low quality in clinical and statistical designs; third, detection
methods of SAA were different in these studies. In the
future, it is very crucial to compare the SAA status in
different histology classification of lung cancer with large
samples, multiple clinical centers. Although some deficien-
cies existed, the study still drew a conclusion that the SAA
assay could be advantageous in the diagnosis of lung cancer,
especially for LSCC.
Conclusions
Patients with lung cancer showed a higher SAA level than
those of healthy individuals, suggesting that increased SAA
correlated with the occurrence and development of lung
cancer. In addition, the fact, SAA has a relatively higher
specificity, suggested that SAA could be a new biomarker
for discerning lung cancer, especially for LSCC.
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